CareDx, Inc (CDNA)
Price:
12.17 USD
( + 0.60 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
IDEXX Laboratories, Inc.
VALUE SCORE:
8
2nd position
GRAIL, Inc.
VALUE SCORE:
9
The best
Medpace Holdings, Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
NEWS

CareDx (CDNA) EPS Beats Sales Gain 14%
fool.com
2025-08-06 23:42:58CareDx (CDNA) EPS Beats Sales Gain 14%

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 22:47:14CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.

Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
zacks.com
2025-08-06 19:32:26The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
zacks.com
2025-08-06 18:45:35CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
businesswire.com
2025-08-06 16:57:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth p.

CareDx Announces Second Quarter 2025 Financial Results
businesswire.com
2025-08-06 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
businesswire.com
2025-08-06 12:56:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of.

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
businesswire.com
2025-07-31 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 World Transplant Congress (WTC), demonstrating advances in artificial.

CareDx to Report Second Quarter 2025 Financial Results
businesswire.com
2025-07-23 07:05:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim.

CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?
zacks.com
2025-07-22 08:10:15CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
businesswire.com
2025-07-18 08:00:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft Local Coverage Determination (LCD) related to molecular testing for solid organ allograft rejection. There is no change in current coverage and the draft LCD is open.

CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
seekingalpha.com
2025-06-14 07:23:41CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.

CareDx Announces Repurchase of 5% of Outstanding Shares
businesswire.com
2025-06-03 16:30:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seven.

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
businesswire.com
2025-05-22 09:27:00SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDx insiders caused the company to issue false and misleading public statements regarding its compliance with health.

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
globenewswire.com
2025-05-21 20:48:00SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.

CareDx to Participate in Upcoming Investor Conferences
businesswire.com
2025-05-13 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health.
No data to display

CareDx (CDNA) EPS Beats Sales Gain 14%
fool.com
2025-08-06 23:42:58CareDx (CDNA) EPS Beats Sales Gain 14%

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 22:47:14CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.

Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
zacks.com
2025-08-06 19:32:26The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
zacks.com
2025-08-06 18:45:35CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
businesswire.com
2025-08-06 16:57:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth p.

CareDx Announces Second Quarter 2025 Financial Results
businesswire.com
2025-08-06 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
businesswire.com
2025-08-06 12:56:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of.

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
businesswire.com
2025-07-31 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 World Transplant Congress (WTC), demonstrating advances in artificial.

CareDx to Report Second Quarter 2025 Financial Results
businesswire.com
2025-07-23 07:05:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim.

CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?
zacks.com
2025-07-22 08:10:15CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
businesswire.com
2025-07-18 08:00:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft Local Coverage Determination (LCD) related to molecular testing for solid organ allograft rejection. There is no change in current coverage and the draft LCD is open.

CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
seekingalpha.com
2025-06-14 07:23:41CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.

CareDx Announces Repurchase of 5% of Outstanding Shares
businesswire.com
2025-06-03 16:30:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seven.

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
businesswire.com
2025-05-22 09:27:00SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDx insiders caused the company to issue false and misleading public statements regarding its compliance with health.

Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
globenewswire.com
2025-05-21 20:48:00SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.

CareDx to Participate in Upcoming Investor Conferences
businesswire.com
2025-05-13 16:01:00BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health.